Hot Features
Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development and commercialization of pharmaceutical products for the treatment of human disease. Some of its drugs candidates are LX9211, an orally-delivered small molecule drug candidate, as a treatment for ... Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development and commercialization of pharmaceutical products for the treatment of human disease. Some of its drugs candidates are LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain; and sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for heart failure and type 1 diabetes. Mehr anzeigen
Strong Interest in Trial Participation Resulted in Enrollment Exceeding Target by 20 Percent and Completion Ahead of Schedule Top-line Data Expected in Q1 2025 THE WOODLANDS, Texas, Nov. 26, 2024...
THE WOODLANDS, Texas, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that company management, including Mike Exton, Lexicon’s chief executive...
Implementing Strategic Restructuring to Eliminate Commercial Organization and Rationalize Operations Across All Functions Prioritizing Strong R&D Pipeline Including Ongoing Studies in DPNP...
THE WOODLANDS, Texas, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Ivan H. Cheung has been elected to its Board of Directors. Mr. Cheung is...
THE WOODLANDS, Texas, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that data from four studies of sotagliflozin will be delivered during the...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.11 | -13.4146341463 | 0.82 | 0.8596 | 0.7045 | 1996505 | 0.80932089 | CS |
| 4 | -0.49 | -40.8333333333 | 1.2 | 1.345 | 0.7045 | 3544514 | 0.99314186 | CS |
| 12 | -0.926 | -56.6014669927 | 1.636 | 2.175 | 0.7045 | 3198397 | 1.42225495 | CS |
| 26 | -1.01 | -58.7209302326 | 1.72 | 2.45 | 0.7045 | 3018379 | 1.63991069 | CS |
| 52 | -0.43 | -37.7192982456 | 1.14 | 3.73 | 0.7045 | 3332872 | 1.89432867 | CS |
| 156 | -3.92 | -84.6652267819 | 4.63 | 4.719 | 0.7045 | 1930576 | 2.02384719 | CS |
| 260 | -2.6 | -78.5498489426 | 3.31 | 9.65 | 0.7045 | 2099645 | 2.98167589 | CS |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
